Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era

<div>Effect of length of follow-up (beta 0.07; 0.03–0.09), of optimal medical therapy (0.02; 0.01–0.04), of CABG (0.04; −0.01–−0.06), and of PCI (0.03; 0.02–0.07) on CV events.</div>

Scientifica

fig4

Figure 4

Figure 4: Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era 

Figure 4 | Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era 